Apop Biosciences enters into worldwide out-license agreement

Apop Biosciences Pty Ltd (Apop) has entered into a worldwide out-license agreement with a U.S.-based company for Apop’s monoclonal antibody technology. Through this agreement, Apop will grant non-exclusive global rights to the licensee to develop, manufacture, and commercialize products that will incorporate Apop’s patented technology.